Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN-6400
- Development stage
- Phase 2
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALN-6400 is an investigational small interfering RNA (siRNA) therapeutic developed by Alnylam Pharmaceuticals. It is designed to target liver-derived plasminogen via RNA interference, aiming to act as a universal hemostatic agent for the treatment of bleeding disorders without increasing the risk of thrombosis. The drug leverages Alnylam's proprietary RNAi technology platform and represents a new molecular entity in clinical development. As of early 2025, ALN-6400 has completed Phase I trials in healthy volunteers and is expected to enter Phase II studies for bleeding disorders later in 2025[1][2][8].
- Other names
- ALN 6400ALN6400ALN-6400
02
Targets
PLG (Plasminogen)
Beyond the preview
Go deeper on ALN-6400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN-6400.